-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Mantle cell lymphoma is a rare and often highly invasive non-Hodgkin lymphoma (NHL).
Lymphoma
Tecartus is a CAR-T cell therapy targeting CD19 .
Tecartus is a CAR-T cell therapy targeting CD19 .
The new NICE guidelines point out that this treatment can be considered for patients with relapsed and refractory mantle cell lymphoma.
NICE has reached an agreement with manufacturer Kite through the Cancer Drug Fund (CDF) to collect more data while patients receive treatment.
fund
A study conducted by NICE's independent evaluation committee on Tecartus showed that patients treated with CAR-T cell therapy may live longer and have longer intervals between disease recurrences.
Original source:
Original source:https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here